17 September 2021
ECO Animal Health Group plc ("the Company")
(AIM: EAH)
Result of Annual General Meeting
ECO Animal Health Group plc announces that at its Annual General Meeting held yesterday ("AGM") all resolutions proposed to the meetings were duly passed on a poll.
The total votes cast on each resolution were as follows:
| Resolution | For |
% | Against |
% | Withheld |
| 01 | 43,796,904 |
82.21 | 9,475,398 |
17.79 | 116,806 |
| 02 | 53,273,110 |
100.00 | Nil |
0.00 | 115,998 |
| 03 | 48,237,828 |
90.55 | 5,034,474 |
9.45 | 116,806 |
| 04 | 53,266,771 |
99.99 | 5,531 |
0.01 | 116,806 |
| 05 | 53,099,474 |
99.68 | 171,110 |
0.32 | 118,524 |
| 06 | 52,624,200 |
98.79 | 643,102 |
1.21 | 121,806 |
| 07 | 53,265,527 |
99.99 | 5,083 |
0.01 | 118,498 |
|
08 | 52,323,802 |
98.22 | 948,283 |
1.78 | 117,023 |
Contacts:
|
ECO Animal Health Group plc Marc Loomes (CEO) Christopher Wilks (CFO)
|
|
| IFC Advisory Graham Herring Zach Cohen
| 020 3934 6630
|
| Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas
| 020 7496 3000 |
| Peel Hunt LLP (Joint Broker) James Steel Dr Christopher Golden | 020 7418 8900 |
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new product
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
